Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia

Kosuke Doki • Masato Homma • Keisuke Kuga •
Kazutomi Kusano • Shigeyuki Watanabe •
Iwao Yamaguchi • Yukinao Kohda

Published online: 15 December 2006
© Springer-Verlag 2006

Erratum to: Eur J Clin Pharmacol 62:919–926
DOI 10.1007/s00228-006-0188-x

Some superscripts and subscripts in Tables 3 and 4 were typeset incorrectly. The correct tables are reproduced here.

The online version of the original article can be found at: <http://dx.doi.org/10.1007/s00228-006-0188-x>.

K. Doki • M. Homma (✉) • Y. Kohda
Department of Pharmaceutical Sciences,
Graduate School of Comprehensive Human Sciences,
University of Tsukuba,
Ten-nodai 1-1-1,
Tsukuba, Ibaraki 305-8575, Japan
e-mail: masatoh@md.tsukuba.ac.jp

K. Kuga • S. Watanabe • I. Yamaguchi
Department of Internal Medicine,
Graduate School of Comprehensive Human Sciences,
University of Tsukuba,
Ten-nodai 1-1-1,
Tsukuba, Ibaraki 305-8575, Japan

K. Kusano
Tsukuba Research Laboratories, Eisai,
Tokodai 5-1-3,
Tsukuba, Ibaraki 300-2635, Japan

Table 3 Summary of analysis models for the pharmacokinetic parameters of flecainide

Number	Model equation	OFV	ΔOFV	Comparison	P value*
1	$V/F = \theta_1 \quad CL/F = \theta_2 \cdot e^{\eta_i}$	816.0	–	–	–
2	$V/F = \theta_1 \quad CL/F = \theta_2 \cdot WT^{\theta_3} \cdot e^{\eta_i}$	798.7	17.3	vs 1	$P < 0.005$
3	$V/F = \theta_1 \quad CL/F = \theta_2 \cdot WT^{\theta_3} \cdot \theta_4^{AGE \geq 70} \cdot e^{\eta_i}$	779.0	19.7	vs 2	$P < 0.005$
4	$V/F = \theta_1 \quad CL/F = \theta_2 \cdot WT^{\theta_3} \cdot \theta_4^{AGE \geq 70} \cdot \theta_5^{SEX} \cdot e^{\eta_i}$	772.4	6.6	vs 3	$P < 0.05$
5	$V/F = \theta_1 \quad CL/F = \theta_2 \cdot WT^{\theta_3} \cdot \theta_4^{AGE \geq 70} \cdot \theta_5^{SEX} \cdot Scr^{\theta_6} \cdot e^{\eta_i}$	760.9	11.5	vs 4	$P < 0.005$
6	$V/F = \theta_1$ $CL/F = \theta_2 \cdot WT^{\theta_3} \cdot \theta_4^{AGE \geq 70} \cdot \theta_5^{SEX} \cdot Scr^{\theta_6} \cdot (\theta_E \cdot EM + \theta_I \cdot IM + \theta_P \cdot PM) \cdot e^{\eta_i}$	750.7	10.2	vs 5	$P < 0.05$

OFV, the objective function value (−2 log likelihood); ΔOFV, difference in OFV; Ka=0.6 (fixed); WT is body weight (kg), AGE≥70 is one for 70 years or over and 0 for otherwise, SEX is 1 for females and 0 for males, Scr is serum creatinine concentration (mg/dL), EM, IM and PM number of EM, IM and PM (poor metabolizer) alleles, respectively.

*The ΔOFV greater than 3.84 (df=1) or 7.81 (df=3) was accepted as statistically significant ($P < 0.05$).

Table 4 Final population pharmacokinetic parameter estimates for flecainide

Parameter	Estimates	CV%
V/F (l)		
$V/F = \theta_1$		
θ_1	379.0	15.7
CL/F (L/h)		
$CL/F = \theta_2 \cdot WT^{\theta_3} \cdot \theta_4^{AGE \geq 70} \cdot \theta_5^{SEX} \cdot Scr^{\theta_6} \cdot (\theta_E \cdot EM + \theta_I \cdot IM + \theta_P \cdot PM)$		
θ_2	1.25	54.7
θ_3	0.49	27.9
θ_4	0.70	7.0
θ_5	0.76	6.1
θ_6	−0.35	39.0
θ_E	1.04	8.7
θ_I	0.82	11.5
θ_P	0.71	17.1
Interpatient variability (%)		
CL/F	17.8	47.5
Intrapatient variability (%)		
CL/F	13.1	50.0

WT Body weight (kg); AGE≥70 is 1 for 70 years or over and 0 for otherwise; SEX is 1 for females and 0 for males; Scr serum creatinine concentration (mg/dL), EM, IM and PM number of EM, IM and PM alleles, respectively. V/F Distribution volume, CL/F oral clearance